← board
IBO
distress 7/10 · high distress / dilution risk$0.44+3%today-43% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
+785%
Price & events
-7.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+3.0%
1D
-2.9%
1W
-17.7%
1M
-32.4%
3M
-6.1%
6M
-37.6%
1Y
—
2Y
—
5Y
-83.5%
All
Overview
- Market Cap
- $47.76M
- Volume
- 2.03K
- 52 Week Range
- $0.40 – $0.78
- Total Shares
- 107.82M
- Float Shares
- 11.49M
- Short %
- 4.74%
- % Held by Insiders
- 89.02%
- % Held by Institutions
- 3.45%
- RVOL
- 0.03x
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2025-06-21partnershipEntry into Merger and Share Exchange Agreement with Dr Ashleys Cayman.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.